IL17A and neoplasm: This initiates signaling events that culminate to stimulate the LPS-induced MyD88 dependent production of IL-1β and IL-23 that differentiates IL-17-producing innate lymphoid cells (83) to produce IL-6 and IL-17 during tumor-promoting events.